Ozempic vs. Wegovy: A Physician's Comparison (2026)

Same Molecule

Same Drug, Different Labels

The active ingredient in both Ozempic and Wegovy is semaglutide. Novo Nordisk runs them as separate brands because the FDA approves each medication for specific indications at specific doses. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly and, after the 2024 SELECT-based label expansion, for cardiovascular-event reduction in adults with overweight or obesity and established cardiovascular disease.

The clinical and commercial implications are substantial. Ozempic is widely covered by commercial insurance for diabetes; Wegovy requires the plan's obesity-drug benefit and a separate prior authorization with BMI-based criteria. Ozempic's list price is roughly $936–$998 per month; Wegovy's is approximately $1,349.

Ozempic

Ozempic — the diabetes brand of semaglutide

Ozempic's labeled use is type 2 diabetes management and cardiovascular risk reduction in patients with diabetes and established cardiovascular disease. Most commercial plans cover it broadly with prior authorization; Medicare Part D covers it for diabetes (not weight loss). At the 2 mg dose, real-world weight loss is typically 6–10% — meaningful but smaller than the 2.4 mg evidence base.

Clinical fit: adults with type 2 diabetes who also benefit from modest-to-moderate weight loss, patients with diabetes and prior cardiovascular events, and patients who prefer the longest real-world track record in this drug class.

Wegovy

Wegovy — the weight-management brand of semaglutide

Wegovy's labeled use is chronic weight management in adults with BMI ≥30 (or ≥27 with a comorbidity), adolescents 12+ with obesity, and — after SELECT — cardiovascular-event reduction in adults with overweight or obesity and established cardiovascular disease. In STEP 1, mean weight loss was ~14.9% at 68 weeks. STEP 4 demonstrated continued therapy is required to sustain weight loss.

Clinical fit: adults whose primary clinical target is weight loss with or without diabetes, patients who meet the SELECT cardiovascular indication, and patients with obesity-drug insurance benefits or willingness to use NovoCare Pharmacy self-pay at $499/month.

Decision Framework

Which One Is Right for You?

• ·Diagnosis on the prescription: type 2 diabetes points to Ozempic; obesity or overweight-with-comorbidity points to Wegovy.
• ·Magnitude of weight loss needed: 6–10% on Ozempic 2 mg versus ~15% on Wegovy 2.4 mg in trials — pick the dose that matches the target.
• ·Cardiovascular history: overweight/obesity + established CVD with no diabetes is the SELECT indication for Wegovy specifically.
• ·Insurance: confirm whether your plan covers Wegovy under an obesity-drug benefit; if not, NovoCare Pharmacy self-pay is $499/month for all doses.
• ·Cost without coverage: Ozempic NovoCare cash ($199 intro → $349–$499) is generally lower than Wegovy NovoCare cash ($499 flat).
• ·Long-term plan: both require ongoing therapy; trials consistently show meaningful weight regain after stopping (STEP 1 extension, STEP 4).

What to Avoid

Compounded semaglutide is not the same product

Compounded semaglutide marketed at $200–$400/month is not FDA-approved. The FDA has documented dosing errors, adverse events, and salt-form substitutions (semaglutide sodium, semaglutide acetate) that are not the same active ingredient as Ozempic or Wegovy. With semaglutide off the FDA shortage list, the legal basis for routine compounding has narrowed sharply. Physicians advise against it.